Ge Long Hui·2025-12-17 14:54Core Viewpoint - The acquisition of 100% equity in Zhejiang Pharmaceutical Industry Co., Ltd. by Guangzhou Pharmaceutical is a strategic move to enhance market presence in the East China region, with a transaction value of RMB 500 million [1] Group 1: Acquisition Details - Guangzhou Pharmaceutical, a subsidiary of the company, has entered into a share purchase agreement to acquire 100% equity of Zhejiang Pharmaceutical from Haizheng Pharmaceutical for RMB 500 million [1] - The acquisition is set to be completed by December 17, 2025, after which Guangzhou Pharmaceutical will hold full ownership of the target company [1] Group 2: Target Company Overview - Zhejiang Pharmaceutical is a leading pharmaceutical distribution enterprise in Zhejiang Province, primarily engaged in the wholesale of various pharmaceutical products [1] - The company reported annual sales revenue exceeding RMB 4 billion in the past year, indicating a strong growth potential [1] Group 3: Strategic Rationale - The acquisition price reflects a premium over the assessed value, which the company considers reasonable based on several factors [1] - The target company is ranked among the top six pharmaceutical distribution enterprises in Zhejiang, providing a well-established customer network and market presence [1] - This acquisition will enable Guangzhou Pharmaceutical to optimize its industrial layout in East China and enhance coverage in the domestic terminal market [1]